Cosmos Health Inc. announced on September 25, 2025, that its wholly owned subsidiary, Cana Laboratories S.A., signed a contract manufacturing agreement with Medical Pharmaquality S.A.
Under the terms of the agreement, Cana will manufacture 3 million MYCOFAGYL® pessaries per year. MYCOFAGYL® is a combination of Metronidazole (500mg) and Nystatin (100,000 IU) for vaginal infections.
This agreement expands Cana’s expertise into gynecology, reinforcing its position as a reliable pharmaceutical manufacturing partner and strengthening the company's high-margin contract manufacturing business.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.